{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:33:49Z","timestamp":1791304429873,"version":"4.3.1"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R44HD075636"],"award-info":[{"award-number":["R44HD075636"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001439"],"award-info":[{"award-number":["UL1 TR001439"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001079"],"award-info":[{"award-number":["UL1 TR001079"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johns Hopkins Center for AIDS Research","award":["P30AI094189"],"award-info":[{"award-number":["P30AI094189"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002655","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:46:36Z","timestamp":1538160396000},"page":"e1002655","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-9551","authenticated-orcid":true,"given":"Kathleen L.","family":"Vincent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8091-3245","authenticated-orcid":true,"given":"John A.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1670-8786","authenticated-orcid":true,"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-8665","authenticated-orcid":true,"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-6782","authenticated-orcid":true,"given":"Peter A.","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-5500","authenticated-orcid":true,"given":"Richard B.","family":"Pyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-1212","authenticated-orcid":true,"given":"Kate M.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevelyn J.","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Butkyavichene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Churchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Fanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Gunawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle K.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-4766","authenticated-orcid":true,"given":"Sara E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-5649","authenticated-orcid":true,"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"ref1","unstructured":"Birx DL. Delivering an AIDS-free generation [Presentation]: The Henry J. Kaiser Family Foundation; 2014."},{"key":"ref2","unstructured":"Fast-Track: Ending the AIDS Epidemic by 2030. Geneva, Switzerland: UNAIDS, 2014."},{"key":"ref3","unstructured":"Prevention Gap Report. Geneva, Switzerland: UNAIDS, 2016."},{"issue":"5996","key":"ref4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women","volume":"329","author":"Q Abdool Karim","year":"2010","journal-title":"Science"},{"issue":"27","key":"ref5","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9883","key":"ref8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral Prophylaxis for HIV Infection in Injecting Drug Users in Bangkok, Thailand (the Bangkok Tenofovir Study): a Randomised, Double-blind, Placebo-controlled Phase 3","volume":"381","author":"K Choopanya","year":"2013","journal-title":"Trial. Lancet"},{"issue":"23","key":"ref9","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"JM Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","article-title":"Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation","volume":"73","author":"JL Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10013","key":"ref11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection (PROUD): Effectiveness Results from the Pilot Phase of a Pragmatic Open-label Randomised Trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e4879","DOI":"10.1136\/bmj.e4879","article-title":"FDA Approves First Drug to Prevent HIV Infection","volume":"345","author":"B. Roehr","year":"2012","journal-title":"B M J"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2055-6640(20)30458-1","article-title":"HIV Pre-exposure Prophylaxis for Women","volume":"2","author":"AN Sheth","journal-title":"J Virus Erad"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s10461-013-0429-9","article-title":"Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials","volume":"17","author":"KR Amico","year":"2013","journal-title":"AIDS Behav"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF00314990","article-title":"Dosage Frequency and Drug Compliance Behavior\u2014a Comparative Study on Compliance with a Medication to Be Taken Twice or 4 Times Daily","volume":"41","author":"W Kruse","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0169-409X(02)00090-X","article-title":"Implantable, Polymeric Systems for Modulated Drug Delivery","volume":"54","author":"S Sershen","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1568005033481079","article-title":"Is Resistance Futile?","volume":"3","author":"VD Kutilek","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","article-title":"Comparing Adherence and Persistence Across 6 Chronic Medication Classes","volume":"15","author":"J Yeaw","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"ref19","first-page":"221","article-title":"Drug Delivery and Development of Anti-HIV Microbicides","author":"JA Moss","year":"2014"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2217\/fvl.15.83","article-title":"Injectable and Implantable Antiretroviral Strategies for HIV Prevention","volume":"10","author":"I McGowan","year":"2015","journal-title":"Future Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women","volume":"375","author":"JM Baeten","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"ref22","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"e0145642","DOI":"10.1371\/journal.pone.0145642","article-title":"The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development","volume":"10","author":"KM Guthrie","year":"2015","journal-title":"PLoS ONE"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.contraception.2015.08.007","article-title":"Meaning-making Matters in Product Design: Users' Sensory Perceptions and Experience Evaluations of Long-acting Vaginal Gels and Intravaginal Rings","volume":"92","author":"RK Rosen","year":"2015","journal-title":"Contraception"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An Intravaginal Ring for the Simultaneous Delivery of Multiple Drugs","volume":"101","author":"MM Baum","year":"2012","journal-title":"J Pharm Sci"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1128\/AAC.02871-14","article-title":"Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model","volume":"58","author":"JA Moss","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"e0185946","DOI":"10.1371\/journal.pone.0185946","article-title":"Novel Multipurpose Pod-intravaginal Ring for the Prevention of HIV, HSV, and Unintended Pregnancy: Pharmacokinetic Evaluation in a Macaque Model","volume":"12","author":"JM Smith","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijpharm.2015.09.028","article-title":"An Intravaginal Ring for the Sustained Delivery of Tenofovir Disoproxil Fumarate","volume":"495","author":"MM Baum","year":"2015","journal-title":"Int J Pharm"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1128\/AAC.00391-16","article-title":"Combination Pod-intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model","volume":"60","author":"JA Moss","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/JCM.29.2.297-301.1991","article-title":"Reliability of Diagnosing Bacterial Vaginosis Is Improved by a Standardized Method of Gram Stain Interpretation","volume":"29","author":"RP Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"e93419","DOI":"10.1371\/journal.pone.0093419","article-title":"Cultivated Vaginal Microbiomes Alter HIV-1 Infection and Antiretroviral Efficacy in Colonized Epithelial Multilayer Cultures","volume":"9","author":"RB Pyles","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: Randomized Pharmacokinetic Cross-over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments","volume":"8","author":"CW Hendrix","year":"2013","journal-title":"PLoS ONE"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jpba.2014.06.018","article-title":"Dual Quantification of Dapivirine and Maraviroc in Cervicovaginal Secretions from Ophthalmic Tear Strips and Polyester-based Swabs via Liquid Chromatographic-tandem Mass Spectrometric (LC-MS\/MS) Analysis","volume":"98","author":"TL Parsons","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)","volume":"32","author":"CW Hendrix","year":"2016","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jpba.2016.08.016","article-title":"Development and Validation of a Liquid Chromatographic-tandem Mass Spectrometric Method for the Multiplexed Quantification of Etravirine, Maraviroc, Raltegravir, and Rilpivirine in Human Plasma and Tissue","volume":"131","author":"TL Parsons","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"ref36","first-page":"22","year":"2001"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jchromb.2016.02.033","article-title":"Accurate Measurement of Female Genital Tract Fluid Dilution in Cervicovaginal Lavage Samples","volume":"1017","author":"SA Churchman","year":"2016","journal-title":"J Chromatogr B"},{"key":"ref38","author":"G Guest","year":"2012"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"e0197269","DOI":"10.1371\/journal.pone.0197269","article-title":"User Evaluations Offer Promise for Pod-intravaginal Ring as a Drug Delivery Platform: A Mixed Methods Study of Acceptability and Use Experiences","volume":"13","author":"KM Guthrie","year":"2018","journal-title":"PLoS ONE"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e3283509abb","article-title":"Tenofovir and Tenofovir Disoproxil Pharmacokinetics from Intravaginal Rings","volume":"26","author":"JA Moss","year":"2012","journal-title":"AIDS"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/CDLI.2.1.57-61.1995","article-title":"Dilution Assessment of Cervicovaginal Secretions Obtained by Vaginal Washing for Immunological Assays","volume":"2","author":"L Belec","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/QAD.0000000000000979","article-title":"A Phase 1 Randomized Placebo-controlled Safety and Pharmacokinetic Trial of a Tenofovir Disoproxil Fumarate Vaginal Ring","volume":"30","author":"MJ Keller","year":"2016","journal-title":"AIDS"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1089\/aid.2013.0044","article-title":"Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue","volume":"29","author":"NA Louissaint","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"e0157061","DOI":"10.1371\/journal.pone.0157061","article-title":"Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-intravaginal Rings Protect Macaques from Multiple SHIV Exposures","volume":"11","author":"P Srinivasan","year":"2016","journal-title":"PLoS ONE"},{"issue":"40","key":"ref46","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal Ring Eluting Tenofovir Disoproxil Fumarate Completely Protects Macaques from Multiple Vaginal Simian-HIV Challenges","volume":"110","author":"JM Smith","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-molecule Inhibitor of Chemokine Receptor CCR5 with Broad-spectrum Anti-human Immunodeficiency Virus Type 1 Activity","volume":"49","author":"P Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/QAI.0000000000000702","article-title":"Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-blind Randomized Trial","volume":"70","author":"BA Chen","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"22","key":"ref49","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women","volume":"375","author":"JM Baeten","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"ref50","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.antiviral.2013.09.019","article-title":"Lessons from Reproductive Health to Inform Multipurpose Prevention Technologies: Don't Reinvent the Wheel","volume":"100","author":"M Brady","year":"2013","journal-title":"Antiviral Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/1471-0528.12851","article-title":"Making the Case for Multipurpose Prevention Technologies: the Socio-epidemiological Rationale","volume":"121","author":"H Boonstra","year":"2014","journal-title":"BJOG"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.addr.2015.02.004","article-title":"Acceptability and Preferences for Vaginal Dosage Forms Intended for Prevention of HIV or HIV and Pregnancy","volume":"92","author":"C Woodsong","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425247.2016.1134485","article-title":"An Update on Multipurpose Prevention Technologies for the Prevention of HIV Transmission and Pregnancy","volume":"13","author":"DR Friend","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(16)30550-3","article-title":"The Promise of Multipurpose Pregnancy, STI, and HIV Prevention","volume":"17","author":"M Quaife","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref56","unstructured":"Baeten J, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E, et al., editors. Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART. 2015 Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb. 23\u201326, 2015; Seattle, WA: CROI, Alexandria, VA."},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10461-016-1458-y","article-title":"Experiences with HPTN 067\/ADAPT Study Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework","volume":"5","author":"KR Amico","year":"2017","journal-title":"AIDS Behav"},{"key":"ref58","unstructured":"Molina J-M, Charreau I, Spire B, Cotte L, Pialoux, Capitant C, et al., editors. On Demand PrEP With Oral TDF-FTC in the Open-Label Phase of the ANRS IPERGAY Trial. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); 2016 Feb. 22\u201325, 2016; Boston, MA: CROI, Alexandria, VA."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T23:15:57Z","timestamp":1662160557000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002655"}},"subtitle":[],"editor":[{"given":"Linda-Gail","family":"Bekker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002655","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]}}}